Phreesia Inc (PHR)

Currency in USD
10.31
+0.14(+1.38%)
Closed·
10.25-0.06(-0.58%)
·
PHR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.0210.34
52 wk Range
7.7725.00
Key Statistics
Prev. Close
10.17
Open
10.12
Day's Range
10.02-10.34
52 wk Range
7.77-25
Volume
526.88K
Average Volume (3m)
871.02K
1-Year Change
-57.3791%
Book Value / Share
6.02
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PHR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.94
Upside
+35.18%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings upwards for the upcoming period

Phreesia Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Analyst Ratings

10 Buy
9 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 13.94
(+35.18% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Raymond James
Hold---DowngradeSep 08, 2026
DA Davidson
Buy13.00+26.09%14.00MaintainSep 04, 2026
Citizens
Hold---MaintainSep 04, 2026
Baird
Hold11.00+6.69%10.00MaintainSep 03, 2026
Wells Fargo
Hold10.00-3.01%9.00MaintainSep 03, 2026

Phreesia Inc SWOT Analysis


Digital Health Pionee
Explore Phreesia's multifaceted platform revolutionizing patient engagement, administrative efficiency, and pharmaceutical marketing in the evolving healthcare IT landscape
Financial Momentum
Delve into Phreesia's impressive revenue growth, improving profitability metrics, and transition to positive adjusted EBITDA and free cash flow generation
Strategic Expansion
Learn how Phreesia's partnerships with large specialty provider networks and diverse revenue streams are driving scalability and market penetration
Market Outlook
Analyst price targets range from $34 to $35, reflecting confidence in Phreesia's growth potential and its positioning as a "growth-at-a-reasonable-price" opportunity
Read full SWOT analysis

Phreesia Inc Earnings Call Summary for Q2/2027

  • Phreesia reported Q2 revenue of $129.5M (up 10% YoY), beating estimates, but adjusted EPS of $0.03 missed forecasts by 66.7%, triggering a 7.59% after-hours drop.
  • Adjusted EBITDA rose to $32.9M with 25% margin; company posted ninth consecutive quarter of positive operating and free cash flow, with net income at $1.9M.
  • Management maintained FY2027 guidance of $510M-$520M revenue and $125M-$135M adjusted EBITDA, citing disciplined spending and revenue mix uncertainty.
  • AccessOne acquisition contributing $37M in revenue; company expects mid-single-digit client growth and investing in AI tools like VoiceAI and PlanMatch.
  • Healthcare services clients grew to 4,744 (up 277 YoY); sequential revenue dip attributed to seasonal payment processing decline after Q1 deductible resets.
Last Updated: 2026/09/02, 23:42
Read Full Transcript

Earnings

Latest Release
Sep 02, 2026
EPS / Forecast
0,03 / 0,09
Revenue / Forecast
129,45M / 129,05M
EPS Revisions
Last 90 days

PHR Income Statement

Compare PHR to Peers and Sector

Metrics to compare
PHR
Peers
Sector
Relationship
P/E Ratio
61.3x12.2x−0.4x
PEG Ratio
0.430.050.00
Price/Book
1.7x2.4x2.6x
Price / LTM Sales
1.3x1.4x3.0x
Upside (Analyst Target)
30.9%18.9%55.1%
Fair Value Upside
Unlock42.7%8.2%Unlock

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.

Employees
1789

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
18,59M29,95%191,66M
Other Institutional Investors
44,26M70,05%456,34M
Public Companies & Retail Investors
0,000,00%0,00
Total
62,85M100,00%648M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Pale Fire Capital SE14,38%8 924 32992 010
BlackRock, Inc.11,31%7 019 83272 374

FAQ

What Is the Phreesia (PHR) Stock Price Today?

The Phreesia stock price today is 10,31 USD.

What Stock Exchange Does Phreesia Trade On?

Phreesia is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Phreesia?

The stock symbol for Phreesia is "PHR."

What Is the Phreesia Market Cap?

As of today, Phreesia market cap is 639,95M USD.

What Is Phreesia's Earnings Per Share (TTM)?

The Phreesia EPS (TTM) is 0,17.

When Is the Next Phreesia Earnings Date?

Phreesia will release its next earnings report on Dec 14, 2026.

From a Technical Analysis Perspective, Is PHR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Phreesia Stock Split?

Phreesia has split 0 times.

How Many Employees Does Phreesia Have?

Phreesia has 1789 employees.

What is the current trading status of Phreesia (PHR)?

As of Sep 13, 2026, Phreesia (PHR) is trading at a price of 10,31 USD, with a previous close of 10,17 USD. The stock has fluctuated within a day range of 10,02 USD to 10,34 USD, while its 52-week range spans from 7,77 USD to 25,00 USD.

What Is Phreesia (PHR) Price Target According to Analysts?

The average 12-month price target for Phreesia is 13,94 USD, with a high estimate of 20 USD and a low estimate of 10 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +35,18% Upside potential.

What Is the PHR Premarket Price?

PHR's last pre-market stock price is 10,09 USD. The pre-market share volume is 200,00, and the stock has decreased by -0,08, or -0,79%.

What Is the PHR After Hours Price?

PHR's last after hours stock price is 10,25 USD, the stock has decreased by -0,06, or -0,58%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.